TISIDB

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Apical cell membrane Multi-pass membrane protein Note=Expressed at the apical membrane of normal tall thyrocytes and of colonic epithelial cells.
Domain	PF00474 Sodium
Function	Acts as an electrogenic sodium (Na(+)) and chloride (Cl-)-dependent sodium-coupled solute transporter, including transport of monocarboxylates (short-chain fatty acids including L-lactate, D-lactate, pyruvate, acetate, propionate, valerate and butyrate), lactate, mocarboxylate drugs (nicotinate, benzoate, salicylate and 5-aminosalicylate) and ketone bodies (beta-D-hydroxybutyrate, acetoacetate and alpha-ketoisocaproate), with a Na(+):substrate stoichiometry of between 4:1 and 2:1. Catalyzes passive carrier mediated diffusion of iodide. Mediates iodide transport from the thyrocyte into the colloid lumen through the apical membrane. May be responsible for the absorption of D-lactate and monocarboxylate drugs from the intestinal tract. Acts as a tumor suppressor, suppressing colony formation in colon cancer, prostate cancer and glioma cell lines. May play a critical role in the entry of L-lactate and ketone bodies into neurons by a process driven by an electrochemical Na(+) gradient and hence contribute to the maintenance of the energy status and function of neurons.

> Gene Ontology [ TOP ]
Biological Process	GO:0006814 sodium ion transport GO:0006820 anion transport GO:0015672 monovalent inorganic cation transport GO:0015711 organic anion transport GO:0015718 monocarboxylic acid transport GO:0046942 carboxylic acid transport
Molecular Function	GO:0005342 organic acid transmembrane transporter activity GO:0008028 monocarboxylic acid transmembrane transporter activity GO:0015291 secondary active transmembrane transporter activity GO:0015293 symporter activity GO:0022803 passive transmembrane transporter activity GO:0022804 active transmembrane transporter activity GO:0046943 carboxylic acid transmembrane transporter activity
Cellular Component	GO:0016324 apical plasma membrane GO:0045177 apical part of cell

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-425374: Amino acid and oligopeptide SLC transporters R-HSA-1430728: Metabolism R-HSA-196854: Metabolism of vitamins and cofactors R-HSA-196849: Metabolism of water-soluble vitamins and cofactors R-HSA-197264: Nicotinamide salvaging R-HSA-196807: Nicotinate metabolism R-HSA-428643: Organic anion transporters R-HSA-425407: SLC-mediated transmembrane transport R-HSA-382551: Transmembrane transport of small molecules R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-425374: Amino acid and oligopeptide SLC transporters
R-HSA-1430728: Metabolism
R-HSA-196854: Metabolism of vitamins and cofactors
R-HSA-196849: Metabolism of water-soluble vitamins and cofactors
R-HSA-197264: Nicotinamide salvaging
R-HSA-196807: Nicotinate metabolism
R-HSA-428643: Organic anion transporters
R-HSA-425407: SLC-mediated transmembrane transport
R-HSA-382551: Transmembrane transport of small molecules
R-HSA-425393: Transport of inorganic cations/anions and amino acids/oligopeptides

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SLC5A8 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between SLC5A8 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
25984582	Colon Carcinoma	Inhibit immunity (T cell function)	Slc5a8-null DCs do not induce IDO1 and Aldh1A2 and do not generate Tregs or suppress IFN-γ-producing T-cells in response to butyrate.

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SLC5A8 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SLC5A8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.499	0.486
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.799	0.494
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.137	0.91
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.458	0.562
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	1.092	0.496
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-2.004	0.299
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.258	0.821
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.216	0.41
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.045	0.873

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SLC5A8 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	8.2	-0.8	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	23.8	5.9	17.9	0.197
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	37.5	0	37.5	0.209
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	9.1	6.3	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	14.3	-14.3	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	0	10.5	0.135
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	0	13.6	0.279
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SLC5A8. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SLC5A8. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SLC5A8. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SLC5A8. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SLC5A8 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SLC5A8 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SLC5A8
Name	solute carrier family 5 (sodium/monocarboxylate cotransporter), member 8
Aliases	AIT; solute carrier family 5 (iodide transporter), member 8; SMCT; SMCT1; apical iodide transporter; electro ......
Chromosomal Location	12q23.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SLC5A8 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse SLC5A8